Related Experiment Videos
Protection of MLV vector particles from human complement
S Breun1, B Salmons, W H Günzburg
1Institute of Virology, University of Veterinary Sciences, Veterinärplatz 1, Vienna, A-1210, Austria.
Biochemical and Biophysical Research Communications
|October 21, 1999
Summary
Murine leukemia virus (MLV) vectors are vulnerable to human complement. Expressing CD59 on packaging cells protected them and improved MLV vector resistance to complement-mediated inactivation.
Area of Science:
- Biotechnology
- Immunology
- Virology
Background:
- Murine cell-derived Moloney murine leukemia virus (MLV) vector particles are typically susceptible to lysis mediated by the human complement system.
- The human complement system poses a significant challenge for the in vivo application of MLV vectors.
Purpose of the Study:
- To investigate the protective effect of expressing the human complement inhibitor CD59 on murine packaging cells.
- To determine if CD59 incorporation into MLV vector particles enhances their resistance to human complement.
Main Methods:
- Murine packaging cells were engineered to express human CD59.
- The susceptibility of CD59-expressing cells and the resulting MLV vector particles to human complement-mediated lysis was assessed.
Main Results:
- Expression of CD59 on murine packaging cells conferred partial protection against human complement-mediated lysis.
- CD59 was successfully incorporated into MLV vector particles produced by these cells.
- The resulting CD59-containing MLV vector particles exhibited enhanced resistance to inactivation by human complement.
Conclusions:
- Engineering murine packaging cells to express CD59 can partially protect the cells from complement lysis.
- Incorporation of CD59 into MLV vectors improves their resistance to human complement-mediated inactivation, potentially enhancing their therapeutic applicability.